Home > Quotes > LLY

Eli Lilly and Company Stock Quote & Summary Data

LLY 
$63.08
*  
0.31
0.49%
Get LLY Alerts
*Delayed - data as of Jul. 29, 2014 12:27 ET  -  Find a broker to begin trading LLY now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    LLY Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
1 Year Target: 63
Today's High/Low:  / 
Share Volume:
90 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today's trading to the average daily volume. 4,524,114
Previous Close: $ 63.39
52 Week High /Low: $ 65.70 / $ 47.53
Market cap "Market Capitalization" is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. �Market Capitalization� is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements. $ 70,614,971,729
P/E Ratio: 20.09
Forward P/E(1y) A widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Average EPS (Earnings Per Share) Estimate for the specified fiscal time period. The forward P/E refers to the value for the next full year. 22.72
Earnings Per Share (EPS) The EPS listed on our infoquote and Summary Quote page is "12-mos Rolling". EPS represents the portion of a company's profit allocated to each outstanding share of common stock. Net income (reported or estimated) for a period of time is divided by the total number of shares outstanding (TSO) during that period; See growth rate measures for EPS. Our vendor's methodology for the EPS on the infoquote and Summary Quote pages follows the EPS used by the majority of the analysts following the stock, in many cases this is EBITDA EPS. $ 3.14
Annualized dividend $ 1.96
Ex Dividend Date May 13, 2014
Dividend Payment Date Jun. 10, 2014
Current Yield 3.09 %
Beta 1.04

Intraday Chart

ETFs with LLY as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
5.57% iShares U.S. Pharmaceutical ETF (IHE) -2.35  (-1.75%)
5.04% PowerShares Dynamic Pharmaceuticals (PJP) -0.53  (-0.88%)
4.62% Merrill Lynch Pharmaceutical HOLDRS (PPH) +1.45  (2.42%)
3.24% SPDR S&P Pharmaceuticals ETF (XPH) -5.72  (-5.58%)
2.66% First Trust Morningstar Dividend Leaders Index Fund (FDL) +2.02  (9.16%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

Eli Lilly and Company (the “company” or “registrant” or "Lilly") was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and market products in two business segments—human pharmaceutical products and animal health products. The mission of our human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Our strategy is to create value for all our stakeholders by accelerating the flow of innovative new medicines that provide improved outcomes for individual patients. Most of the products we sell today were discovered or developed by our own scientists, and our success depends to a great extent on our ability to continue to discover, develop, and bring to market innovative new medicines.  ... More ...  

News for LLY

Consensus Recommendation

Research Brokers before you trade

Want to trade FX?